Gary Lyons

Gary Lyons

DirectoratTravere Therapeutics· In proxies 2022–2025

Gary Lyons sits on 10 public boards.

Boards2

  • Neurocrine BiosciencesDirector · 32 yr on the boardIndependentScience and Medical Technology—Paid as an executive
  • Travere TherapeuticsDirector · 11 yr on the boardIndependent—Paid as an executive

Board seats come from each company's latest proxy statement.

Experience

  1. Travere TherapeuticsPublic company · 3 yr
    • Director2023 – Present · 3 yrStock in role +158%
  2. Neurocrine BiosciencesPublic company · 4 yr
    • Director2022 – Present · 4 yrNo stock prices for these years
  3. Neurocrine BiosciencesPublic company
    • Director? – PresentNo stock prices for these years
  4. Travere TherapeuticsPublic company
    • Director? – PresentNo stock prices for these years
  5. Eledon Pharmaceuticals, Inc.Public company
    • Director? – PresentNo stock prices for these years
  6. Facet Biotech CorporationPublic company
    • Director? – PresentNo stock prices for these years
  7. Fresh Tracks Therapeutics, Inc.Public company
    • Director? – PresentNo stock prices for these years
  8. Rigel Pharmaceuticals, Inc.Public company · 19 yr
    • Director2005 – 2024 · 19 yrNo stock prices for these years
  9. Brickell Biotech, Inc.Public company · 4 yr
    • Director2019 – 2023 · 4 yrNo stock prices for these years
  10. Novus Therapeutics, Inc.Public company · 6 yr
    • Director2017 – 2023 · 6 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?